Stockscreener 앱 받기
0.6745
0.43%
-0.0029
시간 외 거래:
.61
-0.0645
-9.56%
전일 마감가:
$0.6774
열려 있는:
$0.673
하루 거래량:
412.00K
Relative Volume:
0.08
시가총액:
$20.37M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.0441
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
+1.41%
1개월 성능:
+29.36%
6개월 성능:
-15.48%
1년 성능:
-69.27%
1일 변동 폭
$0.6569
$0.6774
1주일 범위
$0.6112
$0.73
52주 변동 폭
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.6745 | 19.81M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech MBRX 2025Q2 Earnings Preview Upside Potential Driven by Strategic Developments - AInvest
Moleculin Biotech shares fall 5.11% intraday despite promising preclinical data for Annamycin. - AInvest
Moleculin Biotech announces preclinical data of annamycin in liver cancer - TipRanks
Moleculin Biotech Reveals Promising Preclinical Data for Annamycin - TipRanks
Moleculin Biotech Highlights Annamycin's Potential Against Liver Cancers with Promising Preclinical Data - Quiver Quantitative
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment - GlobeNewswire
Revolutionary Cancer Treatment: Moleculin's Annamycin Targets 3 Types of Liver Cancer Without Heart Risks - Stock Titan
What is Moleculin Biotech Inc. company’s growth strategyMaximize returns with expert trading insights - Jammu Links News
Is Moleculin Biotech Inc. a good long term investmentAchieve unparalleled market performance - Jammu Links News
How does Moleculin Biotech Inc. compare to its industry peersInvest smarter with high-probability setups - Jammu Links News
Is it the right time to buy Moleculin Biotech Inc. stockUnlock real-time trading signals for gains - Jammu Links News
What makes Moleculin Biotech Inc. stock price move sharplyBuild a diversified portfolio for steady profits - Jammu Links News
What are the latest earnings results for Moleculin Biotech Inc.Capitalize on emerging trends for profits - Jammu Links News
What catalysts could drive Moleculin Biotech Inc. stock higher in 2025Robust financial gains - Jammu Links News
How volatile is Moleculin Biotech Inc. stock compared to the marketFree Stock Market Forecast Reports - Jammu Links News
How strong is Moleculin Biotech Inc. company’s balance sheetFree Stock Market Mentorship - Jammu Links News
Moleculin Biotech Releases Corporate Presentation Update - The Globe and Mail
Moleculin receives notice of intent to grant new European patent for Annamycin - MSN
Moleculin Biotech Inc. Ranks High in Smart Money TrackerROI Driven Equity Selection With Safety Emphasized - metal.it
What Caused the Sharp Drop in Moleculin Biotech (MBRX.O)? - AInvest
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin - GlobeNewswire
Will Moleculin Biotech Inc. Stock Benefit from AI and Green Energy TrendsAccurate Buy Point for Momentum Stocks Detected - metal.it
Moleculin receives European patent notice for cancer drug Annamycin By Investing.com - Investing.com Nigeria
Moleculin receives European patent notice for cancer drug Annamycin - Investing.com
Moleculin Biotech Secures European Patent for Annamycin - TipRanks
Moleculin Biotech, Inc. Receives Notice of Intent to Grant European Patent for Annamycin, Strengthening Market Position in Oncology - Quiver Quantitative
Breakthrough Cancer Drug Patent: Moleculin's Non-Cardiotoxic Treatment Gains EU Protection Until 2040 - Stock Titan
Why Did Moleculin Biotech Inc. (MBRX) Soar 10.08%? - AInvest
Statistical indicators supporting Moleculin Biotech Inc.’s strengthIntraday Trend Analysis for Fast Gains Released - metal.it
Why Did Moleculin Biotech Inc. (MBRX) Soar 11.82%? - AInvest
why MBRX is up afterhours - AInvest
Why Moleculin Biotech Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
What are analysts’ price targets for Moleculin Biotech Inc. in the next 12 monthsConsistently exceptional gains - Jammu Links News
When is Moleculin Biotech Inc. stock expected to show significant growthAchieve breakthrough gains with smart trades - Jammu Links News
whats better mbrx or pstv - AInvest
How high can Moleculin Biotech Inc. stock price go in 2025High-margin investment plays - jammulinksnews.com
Moleculin Biotech Inc. Stock Analysis and ForecastExceptional risk-adjusted gains - PrintWeekIndia
What drives Moleculin Biotech Inc. stock priceUnprecedented market success - PrintWeekIndia
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):